Purple Biotech Secures U.S. Patent for NT219 in Cancer Therapy

Purple Biotech ( (PPBT) ) just unveiled an update.

On March 5, 2025, Purple Biotech announced that it has been granted a new U.S. patent for its NT219 therapy in combination with EGFR antibodies, enhancing its global intellectual property protection. This patent supports the company’s efforts in treating cancer patients resistant to EGFR therapies and positions Purple Biotech for potential commercialization of NT219, which is currently advancing into a Phase 2 study for head and neck cancer.

More about Purple Biotech

Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies aimed at overcoming tumor immune evasion and drug resistance. The company’s oncology pipeline includes products such as CM24, NT219, and CAPTN-3, targeting various cancer resistance mechanisms. Purple Biotech is headquartered in Rehovot, Israel.

YTD Price Performance: -39.56%

Average Trading Volume: 78,410

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $7.56M

For a thorough assessment of PPBT stock, go to TipRanks’ Stock Analysis page.